ANI Pharmaceuticals insider sells 500 shares

Accepted by SEC EDGAR 07/14/2026 - 04:02 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ANI Pharmaceuticals Inc. reported that senior vice president, general counsel and secretary Meredith Cook completed an open-market sale of 500 shares of common stock on July 13, 2026 at $81.84 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on September 15, 2025, and Cook now directly holds 77,390 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary 10b5-1

Net Seller: 500 shares

Net Sell 1 txn

Insider Cook Meredith

Role SR. VP, GENERAL COUNSEL & SEC.

Sold 500 shs ($41K)

Share of Position Sold 0.64%

Type	Security	Shares	Price	Value
Sale	Common Stock F1	500	$81.84	$41K

Holdings After Transaction: Common Stock — 77,390 shares (Direct)

Holdings Before and After: Common Stock, 77,890 to 77,390 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

Key Figures

Shares sold: 500 shares Sale price: $81.84 per share Shares owned after transaction: 77,390 shares +2 more

5 metrics

Shares sold 500 shares Open-market sale of ANI Pharmaceuticals common stock on July 13, 2026

Sale price $81.84 per share Price received per share for the 500 shares of common stock sold

Shares owned after transaction 77,390 shares Direct common stock holdings of Meredith Cook following the sale

Net buy/sell shares -500 shares Net insider trading activity reported in this Form 4

10b5-1 plan adoption date September 15, 2025 Date the Rule 10b5-1 trading plan governing this sale was adopted

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4

3 terms

Rule 10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale market

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share sale did ANI Pharmaceuticals (ANIP) disclose for Meredith Cook?

ANI Pharmaceuticals disclosed that Meredith Cook sold 500 shares of common stock at $81.84 per share on July 13, 2026. The open-market sale was reported on Form 4 and conducted under a pre-established Rule 10b5-1 trading plan.

What is Meredith Cook’s position at ANI Pharmaceuticals (ANIP)?

Meredith Cook is an officer of ANI Pharmaceuticals, serving as Senior Vice President, General Counsel and Secretary. She is not listed as a director or a ten percent owner in this Form 4 filing.

How many ANI Pharmaceuticals (ANIP) shares does Meredith Cook own after the reported sale?

Following the reported transaction, Meredith Cook directly owns 77,390 shares of ANI Pharmaceuticals common stock. This post-transaction holding is disclosed in the Form 4 as the total number of shares beneficially owned after the sale.

Was the ANI Pharmaceuticals (ANIP) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan that Meredith Cook adopted on September 15, 2025. Such plans allow pre-scheduled trading according to predetermined instructions.

Did the ANI Pharmaceuticals (ANIP) Form 4 include any option exercises or derivative transactions?

No. The Form 4 reports only a single open-market sale of 500 shares of common stock. The derivative transaction count and exercise share count are both reported as zero, and the derivative summary section is empty.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Meredith

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SR. VP, GENERAL COUNSEL & SEC.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/13/2026		S(1)		500	D	$81.84	77,390	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

Remarks:

	/s/ Meredith W. Cook	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)